The stock of Novavax Inc. (NASDAQ:NVAX) last traded at $7.36, down -4.29% from the previous session.
Data from the available sources indicates that Novavax Inc. (NASDAQ:NVAX) is covered by 6 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $5.00, we find $15.00. Given the previous closing price of $7.69, this indicates a potential upside of 95.06 percent. NVAX stock price is now -6.69% away from the 50-day moving average and -30.43% away from the 200-day moving average. The market capitalization of the company currently stands at $725.99M.
In total, 1 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $20.60 as their price target over the next twelve months.
With the price target maintained at $15, B. Riley Securities recently Upgraded its rating from Neutral to Buy for Novavax Inc. (NASDAQ: NVAX).
In other news, Glenn Gregory M, President, R&D bought 1,000 shares of the company’s stock on Mar 10. The stock was bought for $6,500 at an average price of $6.50. Upon completion of the transaction, the President, R&D now directly owns 14,473 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07, President, R&D Glenn Gregory M bought 2,000 shares of the business’s stock. A total of $14,088 was incurred on buying the stock at an average price of $7.04. This leaves the insider owning 13,473 shares of the company worth $99161.28. Insiders disposed of 24,372 shares of company stock worth roughly $0.18 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVAX stock. A new stake in Novavax Inc. shares was purchased by FIRST TRUST ADVISORS LP during the first quarter worth $4,493,000. VERITION FUND MANAGEMENT LLC invested $624,000 in shares of NVAX during the first quarter. In the first quarter, STRS OHIO acquired a new stake in Novavax Inc. valued at approximately $622,000. MONACO ASSET MANAGEMENT SAM acquired a new stake in NVAX for approximately $474,000. NINEPOINTTWO CAPITAL LLC purchased a new stake in NVAX valued at around $323,000 in the second quarter. In total, there are 307 active investors with 47.00% ownership of the company’s stock.
With an opening price of $7.69 on Friday morning, Novavax Inc. (NASDAQ: NVAX) set off the trading day. During the past 12 months, Novavax Inc. has had a low of $5.61 and a high of $44.63. The fifty day moving average price for NVAX is $7.87 and a two-hundred day moving average price translates $10.51 for the stock.
The latest earnings results from Novavax Inc. (NASDAQ: NVAX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.58, beating analysts’ expectations of -$1.39 by 1.97. This compares to -$6.53 EPS in the same period last year. The net profit margin was -36.70% and return on equity was 82.30% for NVAX. The company reported revenue of $424.43 million for the quarter, compared to $185.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 128.28 percent. For the current quarter, analysts expect NVAX to generate $225.35M in revenue.
Novavax Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
